Forte Biosciences, Inc. (FBRX)

1.2100 +0.0200 (+1.68%) As of 10:22AM EDT. Market open.

Forte Biosciences, Inc.

3060 Pegasus Park Drive
Building 6
Dallas, TX 75247
United States
310 618 6994
https://www.fortebiorx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 5

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Paul A. Wagner Ph.D.	CEO & Chairman	752.5k	N/A	1970
Mr. Antony A. Riley CPA	Chief Financial Officer	456k	N/A	1967
Dr. Hubert C. Chen M.D.	Pres & Chief Scientific Officer	N/A	N/A	1969
Mr. Christopher Roenfeldt	Chief Operating Officer	N/A	N/A	N/A
Mr. Steven Ruhl	Chief Technical Officer	N/A	N/A	1957

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Corporate Governance

Forte Biosciences, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.